Skip to main content

Adding obinutuzumab to bendamustine boosts progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Adding obinutuzumab to bendamustine boosts progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma

User login

Username

Password

Reset your password

Type	Lead	score